Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study

NCT03686345 is registered in ClinicalTrials.gov with Niguarda Hospital as lead sponsor.

NCT NCT03686345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03686345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study
Lead sponsor
Niguarda Hospital
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2018
Completion date
December 31, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

core binding factor acute myeloid leukemia (cbf-aml)